Pulocimab
Based on 1 Customer Validation
Pulocimab (AK109) is an orally active PPARα/γ dual activator with EC50 values of 48 nM and 67 nM, respectively. Pulocimab reduces plasma glucose, improves dyslipidemia, lowers total cholesterol, and raises HDL cholesterol. Pulocimab binds VEGFR2 and blocks VEGF/VEGFR2 signaling, inhibiting angiogenesis, endothelial cell migration, and tumor cell proliferation. Pulocimab can be used for research on type 2 diabetes with dyslipidemia and advanced or metastatic solid tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.42%
- CAS 番号: 2428381-49-9
- 分子量:143.721 kDa
-
保管条件:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
VEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
|
PPARα 48 nM (EC50) |
PPARγ 67 nM (EC50) |
VEGFR2 |
体外実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ob/ob[1]
-
Dosage:0.1 mg/kg
-
Administration:p.o.; once daily; for 14 days
-
Result:Reduced plasma glucose.
- Human pluripotent stem cell endothelial-cell differentiation
- Cell migration
- Somatic Cell Culture
- Zigmond Chamber Chemotaxis Assay
- Under-Agarose Cell Migration Assay
- Transwell/Boyden Chamber Migration Assay
- Endothelial Tube Formation Assay
- 3D Collagen/Hydrogel Matrix Migration Assay
- MTT Cell Proliferation Assay
- Cell-Exclusion Zone Migration Assay
- Dunn/Insall Chamber Chemotaxis Assay
- Endothelial Cell Migration/Angiogenic Sprouting Assay
- Scratch/Wound-Healing Migration Assay
- Vascular/Branching Fractal Analysis
- BrdU Incorporation Assay
- Neural Crest/Neuronal Cell Migration Explant Assay
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Research Protocol for Metabolic Diseases
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized VEGFR-2 Protein, Human (HEK293, His, HY-P70552) can bind Pulocimab. The EC50 for this effect is 19.88 ng/mL.
化学情報
-
CAS 番号 2428381-49-9
-
性状 Liquid
-
分子量 143.721 kDa
-
Color Colorless to light yellow
-
SMILES
[Pulocimab]
-
別名
AK109
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- Pulocimab
- 2428381-49-9
- AK109
- AK 109
- AK-109
- PPAR
- VEGFR
- Peroxisome proliferator-activated receptors
- Vascular endothelial growth factor receptor
- PPARα
- PPARγ
- VEGF/VEGFR2 signaling
- VEGFR2
- angiogenesis
- dyslipidemia
- endothelial cell migration
- solid tumors
- tumor cell proliferation
- type 2 diabetes mellitus
- Inhibitor
- inhibitor
- inhibit